NBI-1076968
Muscarinic M4 receptor antagonist
From Wikipedia, the free encyclopedia
NBI-1076968 is a selective muscarinic acetylcholine M4 receptor antagonist which is under development by Neurocrine Biosciences for the treatment of movement disorders.[1][2] It is orally active.[1][2]
| Clinical data | |
|---|---|
| Other names | NBI1076968 |
| Routes of administration | Oral[1][2] |
| Drug class | Muscarinic acetylcholine M4 receptor antagonist[1][2] |
Pharmacology
Along with the earlier drugs PD-0298029 and PD-102,807, NBI-1076968 is among the only selective M4 receptor antagonists to have been developed to date.[3] However, in contrast to NBI-1076968, the earlier selective antagonists have not had optimal drug-like properties for development as pharmaceutical drugs.[3]
Clinical trials
As of September 2024, NBI-1076968 is in phase 1 clinical trials for treatment of movement disorders.[1] The drug is under development by Neurocrine Biosciences.[1] It was first described in 2024.[1][2]